Tevosol has developed the Ex-Vivo Organ Support System, which utilizes a specialized perfusion technology to maintain organ viability outside the human body. This system increases the availability of transplantable organs, addressing the critical shortage faced by transplant centers.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Transplant centers face a critical shortage of viable organs, leading to long waiting lists and patient mortality. The limited time window for organ preservation outside the body restricts the geographic radius for organ procurement and utilization.
Solution
Tevosol's Ex-Vivo Organ Support System employs a specialized perfusion technology to maintain and assess the viability of organs outside the human body for extended periods. This system expands the window of opportunity for organ transplantation, increasing the availability of transplantable organs and potentially improving patient outcomes. The technology allows for transportation over longer distances and enables comprehensive evaluation of organ function before transplantation.
Target Audience
The primary target audience includes transplant centers, hospitals, and organ procurement organizations seeking to increase the availability and improve the quality of transplantable organs.
Features
- Specialized perfusion technology to maintain organ viability ex-vivo.
- Extended preservation time for organs outside the body.
- Enables transportation of organs over longer distances.
- Facilitates comprehensive assessment of organ function prior to transplantation.